Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine
Go back to Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine| Orexigen Therapeutics, Inc. (NASDAQ: OREX) | Delayed: 0.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.22 | 52 Week High | $4.75 | |||
| Open | $0.04 | 52 Week Low | $0.35 | |||
| Day High | $0.22 | P/E | N/A | |||
| Day Low | $0.22 | EPS | $-1.02 | |||
| Volume | 74,385 | |||||
